Epidermolysis Bullosa Therapeutics Market Size in the 7MM is USD 2,300 million in 2025, which is expected to rise during the forecast period (2026-2036), estimates DelveInsight

DelveInsight's "Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast- 2036" report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Epidermolysis Bullosa market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Epidermolysis Bullosa Market with DelveInsight's In-Depth Report @ Epidermolysis Bullosa Market Size- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Epidermolysis Bullosa Market Report
• In April 2026- TWi Biotechnology Inc. conducted a Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.
• In March 2026- Krystal Biotech, Inc. initiated a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
• In March 2026- Castle Creek Biosciences, LLC announced a study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
• The total prevalent cases of epidermolysis bullosa in the 7MM were ~47,500 cases in 2025, which is expected to increase during the forecast period (2026-2036).
• The highest number of prevalent cases was observed in the United States. On the other hand, within the EU4 and the UK, the UK accounted for the highest number of epidermolysis bullosa cases, with approximately 5,100 cases reported in 2025.
• In Japan, the 0-9 year age group has the highest contribution, followed by the 10-19 year age group, and then those over 19 years of age.
• Epidermolysis bullosa affects males and females equally. The condition is more prevalent in children and young adults, with approximately 78% of cases in the 7MM occurring in individuals under 19 years old in 2025.
• Epidermolysis bullosa simplex is the most common form of epidermolysis bullosa, accounting for approximately 61%, 5%, and 34% cases of EBS, JEB, and DEB in the 7MM in 2025.
• The leading Epidermolysis Bullosa Companies such as Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Phoenix Tissue Repair (BridgeBio Pharma, Inc), Menlo Therapeutics, JCR Pharmaceuticals, Amicus Therapeutics and others.
• Promising Epidermolysis Bullosa Therapies such as Oleogel-S10, SD-101 dermal cream (3%), Diacerein 1% Ointment, and others

Stay ahead in the Epidermolysis Bullosa Therapeutics Market with DelveInsight's Strategic Report @ Epidermolysis Bullosa Market Outlook- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Epidermolysis Bullosa Epidemiology
• Total Prevalent Cases of Epidermolysis Bullosa
• Diagnosed Prevalent Cases of Epidermolysis Bullosa
• Gender-specific Cases of Epidermolysis Bullosa
• Age-specific Cases of Epidermolysis Bullosa
• Type-specific Cases of Epidermolysis Bullosa

Download the report to understand which factors are driving Epidermolysis Bullosa epidemiology trends @ Epidermolysis Bullosa Prevalence- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Epidermolysis Bullosa Approved Therapies
• VYJUVEK (beremagene geperpavec): Krystal Biotech
B-VEC is a non-invasive, topical, redosable gene therapy designed to deliver two copies of the COL7A1 gene when applied directly to DEB wounds. In May 2023, VYJUVEK (beremagene geperpavec-svdt) was approved for treating patients 6 months of age or older with DEB. VYJUVEK is the first-ever redosable gene therapy and the first and only medicine approved by the FDA for treating DEB, both recessive and dominant; a healthcare professional can administer that in either a healthcare professional setting or in the home.

• FILSUVEZ (oleogel-S10): Chiesi Farmaceutici
FILSUVEZ (oleogel-S10/birch triterpenes/formerly known as AP101) is an herbal medicinal product that contains birch triterpenes from birch bark. FILSUVEZ received a marketing authorization valid throughout the EU on 21 June 2022. FILSUVEZ gel is indicated for patients 6 months and older to treat superficial wounds associated with Junctional Epidermolysis Bullosa and Dystrophic Epidermolysis Bullosa. In February 2022, Amryt announced it received a Complete Response Letter (CRL) from the US FDA regarding its New Drug Application (NDA) for Oleogel-S10 for the treatment of the cutaneous manifestations of dystrophic and Junctional Epidermolysis Bullosa. The FDA asked Amryt to submit additional confirmatory evidence of effectiveness for Oleogel-S10 in epidermolysis bullosa. In April 2023, Chiesi Farmaceutici announced the completion of the acquisition of Amryt Pharma.

Emerging Epidermolysis Bullosa Drug
• D-Fi (dabocemagene autoficel): Castle Creek Biosciences
Using its proprietary ex vivo platform, Lenti-VEX, the company is developing and evaluating D-Fi, also known as FCX-007 (dabocemagene autoficel), an autologous gene therapy candidate to treat DEB, a progressive, devastatingly painful and debilitating, rare genetic skin disorder.

• ABCB5+ mesenchymal stem cells (ABCB5+ MSCs): RHEACELL
ABCB5+ mesenchymal stem cells (ABCB5+ MSCs) may represent a new, promising therapeutic approach to epidermolysis bullosa. ABCB5+ MSCs are infused into the bloodstreams and can migrate to the wounds, decreasing inflammation and promoting wound healing. ABCB5+ MSCs target all wounds (internal and external) and release and deposit collagen VII.

Get In-Depth Knowledge on Epidermolysis Bullosa Market Trends and Forecasts with DelveInsight @ Epidermolysis Bullosa Treatment Market- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Epidermolysis Bullosa Market Outlook Significant advances in understanding the pathophysiology of epidermolysis bullosa have driven the development of repurposed drugs and novel targeted therapies, particularly disease-modifying approaches aimed at restoring defective proteins. However, no curative treatments exist for most epidermolysis bullosa subtypes, and current management remains largely supportive, focusing on wound care, pain control, and prevention of complications. Wound care is the cornerstone, but it is time-intensive, costly, and places a substantial burden on patients and caregivers, especially in severe forms such as recessive dystrophic epidermolysis bullosa (RDEB).

Scope of the Epidermolysis Bullosa Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Forecast Period- 2026-2036
• Epidermolysis Bullosa Companies- Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Phoenix Tissue Repair (BridgeBio Pharma, Inc), Menlo Therapeutics, JCR Pharmaceuticals, Amicus Therapeutics and others
• Epidermolysis Bullosa Therapies- Oleogel-S10, SD-101 dermal cream (3%), Diacerein 1% Ointment, and others
• Epidermolysis Bullosa Market Dynamics: Epidermolysis Bullosa Market Drivers and Barriers
• Epidermolysis Bullosa Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Epidermolysis Bullosa Drugs in development @ Epidermolysis Bullosa Clinical Trials Assessment- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary of Epidermolysis Bullosa (EB)
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Epidermolysis Bullosa Market Overview at a Glance
7. Epidermolysis Bullosa (EB): Disease Background and Overview
8. Treatment and Management of Epidermolysis Bullosa
9. Guidelines
10. Epidemiology and Patient Population of 7MM
11. Epidermolysis Bullosa Patient Journey
12. Epidermolysis Bullosa Marketed Drugs
13. Epidermolysis Bullosa Emerging Drugs
14. Epidermolysis Bullosa: 7MM Analysis
15. Epidermolysis Bullosa Unmet needs
16. Epidermolysis Bullosa SWOT Analysis
17. Epidermolysis Bullosa KOL Views
18. Epidermolysis Bullosa Market Access and Reimbursement
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.